In February, Starfish will commence an in-depth clinical study as a follow-up to the pilot study conducted in 2023. The purpose of the study is to verify the results of the previous pilot study, where the Starfish platform demonstrated significantly better outcomes than the solutions currently available on the market.
“We are very confident in the results presented in both the simulation study from 2020 and the pilot study from 2023, where we observed, among other things, a 24% increase in microcirculation compared to the solutions currently in use,” says Micael Gustafsson, CEO of Starfish.
During 2024, the company strengthened its operations and initiated its commercial launch. The ongoing clinical study is a vital part of this process, explains Rickard Dahan, coordinator and clinical trial manager at Starfish:
“In the initial pilot study, we observed clear indications that our solution actually meets the strict requirements we set for the key factors behind pressure ulcers: microcirculation (friction has not yet been tested), temperature, and moisture.
We are ensuring that our research projects maintain a high level of scientific evidence, which is why we are now beginning a more extensive prospective study with researchers from the Faculty of Engineering at Lund University as test and project leaders.”
Starfish has developed a new, innovative method to measure microcirculation in the skin and how it is affected by the surface on which a person lies or sits. “When we initiated the previous study, we were genuinely surprised to discover the lack of reliable and relevant evidence for the solutions currently available on the market. Therefore, it is particularly important to verify that our solution truly works and that it surpasses the standard solutions on the market,” concludes Rickard.
The study is expected to be completed in March, and the results will be published on the Starfish website.
For more information please contact CEO Micael Gustafsson on +46 736993601 or micael.gustafsson@starfishofsweden.com